First Pill for Stress Incontinence in the Works
Yentreve Improves Urinary Incontinence, Reduces Leakage
WebMD News Archive
Aug. 5, 2004 -- Developers of a new drug to treat stress urinary incontinence report favorable findings in a new study.
Yentreve is designed to help increase the tone and contraction of a urethral muscle to help stop urine leaks during physical activity in women.
Stress urinary incontinence is the most common form of incontinence in women, affecting nearly 15 million women in the U.S.
Women with the condition experience urine leaks during activities such as sneezing, coughing, laughing, lifting, and exercise. Obesity, chronic coughing, constipation, and childbirth are among the factors that can trigger stress urinary incontinence.
Eli Lilly and Company, which is partnering with Boehringer Ingelheim to make Yentreve, recently released a study of Yentreve at a meeting of the American Urogynologic Society and the Society of Gynecologic Surgeons. Lilly is a WebMD sponsor.
Researchers surveyed 493 women with stress urinary incontinence. All started by taking placebo for two weeks; afterward, some were switched to Yentreve. Twelve weeks later, the remaining placebo takers were given the option of trying Yentreve.
About 42% reported improvement in urinary leakage when they were taking the placebo. Within a month of taking Yentreve, 67% of those taking the drug said their condition had improved.
After eight more weeks, there was no difference between the percentages of women reporting improvement, regardless of when they started taking Yentreve. In a news release, Eli Lilly medical advisor David Muram, MD, says the results show that Yentreve "can significantly improve" symptoms of stress urinary incontinence in women.
Duloxetine's reported side effects include nausea, fatigue, insomnia, dry mouth, constipation, drowsiness, dizziness, headache, and diarrhea.
Yentreve is not yet on he market. However, the same active drug, generic name duloxetine, was approved earlier this week for the treatment of depression under the brand name Cymbalta.
The drug treats depression by increasing available levels of two chemicals -- serotonin and norepinephrine.
If approved, Yentreve would be the first such pill for treating stress urinary incontinence.
SOURCE:American Urogynecologic Society and the Society of Gynecologic Surgeons Joint Scientific Meeting, San Diego, July 29-31, 2004. News release, Eli Lilly and Company and Boehringer Ingelheim.